MMR CAMPAIGN

The MMR Campaign

Table of Contents

Introduction1

Capital Catch-Up Campaign1

Discussion1

History2

Manufacturing and composition2

Method of vaccination3

Effectiveness4

Contraindications5

Side Effects5

Controversy6

References7

The MMR Catch up Campaign

Introduction

The health promotion issue identified within my setting is the poor uptake of the Measles, Mumps and Rubella (MMR) vaccine. The aim of this report is to inform parents/Careers/Teachers about the importance of having the MMR vaccine.

Capital Catch-Up Campaign

Capital Catch-Up was a London-wide MMR vaccination programme carried out among primary school age children in the capital during the winter of 2004/2005. The primary purpose of the programme was to reduce the risk of community outbreaks of measles in London by decreasing the number of primary school age children susceptible to the disease.

Discussion

The vaccine against measles, mumps and rubella, or MMR or MMR, is a combined vaccine against measles, the rubella and mumps. It corresponds to the MMR vaccine English (measles-mumps-rubella). The MMR vaccine is usually administered to children, but can also be recommended in some cases of infection to HIV in adults. This vaccine is sold by Merck under the name of MMR II, GlaxoSmithKline under the name of Priorix by Serum Institute of India under the name Tresivac and Sanofi Pasteur as the Trimomax.

History

MMR II is a vaccine that was developed by Merck in late 1960. He was fired by that name in 1971 when we began using it. Originally, there was a dose, but in 1989 a second dose was recommended by the American Academy of Family Physicians, the American Academy of Pediatrics and the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. Today, this vaccine is still administered in the world.

Manufacturing and composition

MMR II is made from live attenuated virus strains. The virus strains are produced using cell culture. To feed the virus, buffered saline fetal bovine serum is needed. The culture medium used was medium 199 which is composed mainly of purines, pyrimidines and lipid soluble,. Viruses are thus prolonged growth under conditions that are unusual in prolonged passage. As they multiply, they will lose their infectivity, but without losing their capacity to induce an immune response.

The vaccine is a sterile lyophilized vaccine three or Attenuvax, and MUMPSVAX MERUVAX.

Attenuvax is a vaccine containing a live virus strain of measles. This derives from the attenuated Edmonston Enders and spread in a culture of chicken embryo cells.

MUMPSVAX is the vaccine used against mumps. It contains live, attenuated strain Jeryl Lynn (B type) and is also produced using cell culture embryonic chicken.

MERUVAX attacks, meanwhile, to rubella. This is a live virus vaccine containing an attenuated strain and Wistar RA 27/3 which is created from a culture of WI-38 diploid cells from human lung fibroblasts.

The vaccine also contains an antibiotic called neomycin. This antibiotic is used to prevent contamination by other bacteria or viruses in the vaccine. It can induce allergic reactions on the skin in some patients during administration of MMR vaccine. MMR II also contains other ingredients that remain idle for about virus protection. However, if confirmed by FDA, the vaccine does not contain a preservative such as thimerosal, ...